Radial vs. Femoral Access for Coronary Intervention
A perspective from Population Health Research Institute

Sanjit Jolly MD, MSc FRCPC
Interventional Cardiologist, McMaster University, Hamilton, Canada
Disclosures

- Received honoraria from Sanofi Aventis and Glaxo Smith Kline
- Grant support from Medtronic
OASIS 5: A Randomized, Double-Blind, Double-Dummy Trial

20,078 Patients with NSTE ACS, Chest discomfort < 24 hours
2 of 3: Age>60, ST Segment Δ, ↑ cardiac markers

Randomization
Fondaparinux
2.5 mg subcut daily up to 8 days or hospital discharge
Mean treatment : 5.4 days
Mean time to PCI: 2.4 days

Enoxaparin
1 mg/kg subcut bid for 2-8 days
1 mg/kg subcut daily if ClCr<30mL/min
Mean treatment : 5.2 days
Mean time to PCI: 2.6 days

Aspirin, Clopidogrel, GPIIb/IIIa inhibitor, planned Cath/PCI as per local practice

Exclude
Age < 21
Any contra-ind to Enox
Hem stroke< 12 mo.
Creat> 3 mg/dL/265 umol/L

Michelangelo OASIS 5 Steering Committee. Am Heart J 2005;150:1107.e1-.e10
Radial vs. Femoral Access in OASIS 5 trial

Hamon M, et al. AHA 2006

(during blind study drug administration)
Mortality at 6 months of Radial vs. Femoral Access from OASIS 5

Radial vs. Femoral

HR 0.68
95% CI [0.43-1.07]
p=0.09

Hamon M, et al. AHA 2006
New Paradigms:

1) Major bleeding is as important as MI, in terms of predicting subsequent mortality
2) Major Bleeding events may lead to death and Recurrent MI

Major Bleeding

<table>
<thead>
<tr>
<th>Study name</th>
<th>Radial</th>
<th>Femoral</th>
<th>Peto odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCESS</td>
<td>0 / 300</td>
<td>4 / 300</td>
<td>0.13</td>
</tr>
<tr>
<td>Achenbach</td>
<td>0 / 152</td>
<td>4 / 155</td>
<td>0.14</td>
</tr>
<tr>
<td>Bodi</td>
<td>3 / 666</td>
<td>7 / 332</td>
<td>0.19</td>
</tr>
<tr>
<td>BRAFE</td>
<td>0 / 50</td>
<td>1 / 55</td>
<td>0.15</td>
</tr>
<tr>
<td>FARMI</td>
<td>3 / 57</td>
<td>3 / 57</td>
<td>1.00</td>
</tr>
<tr>
<td>Gorge</td>
<td>1 / 214</td>
<td>1 / 216</td>
<td>1.01</td>
</tr>
<tr>
<td>Mann 1998</td>
<td>0 / 68</td>
<td>2 / 77</td>
<td>0.15</td>
</tr>
<tr>
<td>OCTOPLUS</td>
<td>1 / 192</td>
<td>7 / 185</td>
<td>0.21</td>
</tr>
<tr>
<td>OUTCLAS</td>
<td>0 / 322</td>
<td>1 / 322</td>
<td>0.14</td>
</tr>
<tr>
<td>RADIAM</td>
<td>1 / 25</td>
<td>4 / 25</td>
<td>0.27</td>
</tr>
<tr>
<td>RADIAMI</td>
<td>3 / 50</td>
<td>7 / 50</td>
<td>0.41</td>
</tr>
<tr>
<td>TEMPURA</td>
<td>0 / 77</td>
<td>2 / 72</td>
<td>0.12</td>
</tr>
<tr>
<td>Vazquez-Rodriguez</td>
<td>1 / 217</td>
<td>5 / 222</td>
<td>0.27</td>
</tr>
<tr>
<td></td>
<td>13 / 2390</td>
<td>48 / 2068</td>
<td>0.27</td>
</tr>
</tbody>
</table>

OR 0.27 (95% CI 0.16, 0.45) p<0.001

Death, MI or Stroke

<table>
<thead>
<tr>
<th>Study name</th>
<th>Radial</th>
<th>Femoral</th>
<th>Peto odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCESS</td>
<td>11 / 300</td>
<td>9 / 300</td>
<td>1.23</td>
</tr>
<tr>
<td>Achenbach</td>
<td>0 / 152</td>
<td>1 / 155</td>
<td>0.14</td>
</tr>
<tr>
<td>Bodi</td>
<td>7 / 666</td>
<td>9 / 332</td>
<td>0.35</td>
</tr>
<tr>
<td>BRAFE</td>
<td>2 / 50</td>
<td>2 / 55</td>
<td>1.10</td>
</tr>
<tr>
<td>Cooper</td>
<td>0 / 101</td>
<td>1 / 99</td>
<td>0.13</td>
</tr>
<tr>
<td>FARMI</td>
<td>6 / 57</td>
<td>6 / 57</td>
<td>1.00</td>
</tr>
<tr>
<td>OCTOPLUS</td>
<td>7 / 192</td>
<td>17 / 185</td>
<td>0.40</td>
</tr>
<tr>
<td>OUTCLAS**</td>
<td>7 / 322</td>
<td>7 / 322</td>
<td>1.00</td>
</tr>
<tr>
<td>RADIAL AMI</td>
<td>0 / 25</td>
<td>1 / 25</td>
<td>0.14</td>
</tr>
<tr>
<td>RADIAMI</td>
<td>1 / 50</td>
<td>2 / 50</td>
<td>0.51</td>
</tr>
<tr>
<td>TEMPURA*</td>
<td>4 / 77</td>
<td>6 / 72</td>
<td>0.61</td>
</tr>
<tr>
<td>Vazquez-Rodriguez</td>
<td>11 / 217</td>
<td>10 / 222</td>
<td>1.13</td>
</tr>
<tr>
<td></td>
<td>56 / 2209</td>
<td>71 / 1874</td>
<td>0.71</td>
</tr>
</tbody>
</table>

OR 0.71 (95% CI 0.49, 1.01) p=0.058

- Trend for a reduction in death, MI or stroke with radial

RIVAL study:
Radial Vs. femoral access for coronary intervention in patients with acute coronary syndromes study

Principal Investigator: Sanjit Jolly MD, MSc
Co-Principal Investigator: Shamir Mehta MD, MSc
RIVAL trial

- Definitive Multicenter trial of Radial vs. Femoral Access (N=7000)
- Includes patient with Non ST elevation acute coronary syndromes and STEMI
- Started as a sub-study of the OASIS 7-CURRENT trial
- Continued and has recruited more than 6000 patients in 32 countries (including the U.S.)
Hypothesis of RIVAL trial

- Radial access site PCI will be associated with significantly less major bleeding and access site complications compared with a femoral approach.
- This reduction in bleeding complications will translate into lower rates of death and ischemic complications.
Non STEACS and STEMI (n=7000)

Randomization

Intent to treat Analysis

Radial Access (n=3500)

Femoral Access (n=3500)

30 day follow up

30 day follow up

Primary Outcome: Death, MI, stroke or major bleeding at 30 days
Inclusion Criteria

1. UA/NSTEMI patients AND STEMI patients
2. Suitable candidate for either radial or femoral artery PCI
3. Randomized during index hospitalization for acute coronary syndrome
4. Intent to perform same-sitting angiography and PCI
5. Palpable radial artery with a documented normal Allen’s Test
6. Acceptance by operator to use whichever route is assigned by the randomization process
7. Previous experience of the operator with at least 50 cases of radial artery access within the last year
8. Written informed consent
Outcomes

- **Primary outcome:** Death, MI, Stroke or Major bleeding
- **Secondary outcomes:**
  - Components of primary outcome
  - Non-CABG major bleeding
  - Access site complications
  - Procedural time
  - PCI complication rates
  - Fluoroscopy time
  - Radiation dose
  - Access site cross-over
  - PCI failure rate
Study Definitions

- **Major bleeding:**
  - Fatal,
  - hypotension requiring inotropes,
  - requiring surgery (other than vascular site repair),
  - requiring 2 units of red blood cells, or
  - Drop in 3 g/dl of Hb or greater
  - Intracranial hemorrhage

- **Vascular Access site complication:**
  - Pseudoaneuysm requiring treatment, AV fistula, large hematoma requiring prolonged hospitalization, limb ischemia or damage to adjacent nerve
Summary

- RIVAL trial has potential to show that radial access reduces important clinical outcomes and influence practice